Pharmaceutical Executive February 24, 2025
John Arena, interim president of global pharma services at Cencora, discusses how new technologies are shortening timelines.
Pharmaceutical Executive: What is the funding environment for pharma at the moment?
John Arena: We track the trends in the market, one of which is biopharma funding. Post COVID, there was a decline in biopharma funding, but that has not only stabilized, we’re seeing funding in this area pick up and definitely return to growth. Recent research now shows that 70% of the clinical trials are really in the smaller biotech companies, which is significant. And oftentimes these companies have limited resources and organizational experience to commercialize their overall product. So, the way we position that is if they select the right strategic partner,...
Today's Sponsors
Today's Sponsor